Microbot Medical has a Cash Ratio of 1.69. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Microbot Medical's Cash Ratio or its related term are showing as below:
MBOT'
s Cash Ratio Range Over the Past 10 Years
Min: 1.1 Med: 3.72 Max: 20.43
Current: 1.69
During the past 13 years, Microbot Medical's highest Cash Ratio was 20.43. The lowest was 1.10. And the median was 3.72.
MBOT's Cash Ratio is ranked better than 58.6% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: 1.23
vs MBOT: 1.69
Microbot Medical Cash Ratio Historical Data
The historical data trend for Microbot Medical's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Microbot Medical's Cash Ratio
For the Medical Instruments & Supplies subindustry, Microbot Medical's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Microbot Medical's Cash Ratio Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Microbot Medical's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Microbot Medical's Cash Ratio falls into.
Microbot Medical Cash Ratio Calculation
The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.
Microbot Medical's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Microbot Medical (NAS:MBOT) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Microbot Medical Cash Ratio Related Terms
Thank you for viewing the detailed overview of Microbot Medical's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Microbot Medical (Microbot Medical) Business Description
Microbot Medical Inc is a pre-clinical medical device company. It specializes in developing next-generation micro-robotic medical technologies that can change the future of medicine. Their vision is to improve the quality of life of millions of patients globally by advancing micro-robotic technologies to perform surgical procedures and offer physicians and their patients less invasive and more precise solutions. The company's innovative platforms LIBERTY and Self-Cleaning Shunt (SCS) are in one of the fastest-growing segments in healthcare. The group continuously develops its technology with the goal to improve surgical outcomes worldwide. The firm presently holds domestic and global patents that strengthen its product portfolio and create barriers of entry.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MBOT has been successfully added to your 